Drug Profile
Research programme: autoimmune/inflammatory disorder therapeutics - AstraZeneca
Latest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator Amplimmune
- Developer AstraZeneca
- Class
- Mechanism of Action Cytokine inhibitors; Immunosuppressants; T cell activation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Autoimmune disorders; Inflammation
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
- 04 Oct 2013 Amplimmune has been acquired by MedImmune